EyeYon Medical Raises $25 million in Series C to Transform Corneal Care
EyeYon Medical has developed the world's first synthetic implant that enables doctors to treat chronic corneal edema in a minimally invasive procedure without the use of human tissue or corneal donations.
TEL AVIV, Israel, March 15, 2021 /PRNewswire/ -- EyeYon Medical announced today the completion of a $25 million in a Series C funding, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund. Other participants in the round include Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), BPC and existing investors Triventures, Rimonci, Pontifax and Diamond BioFund.
EyeYon Medical was founded in 2011 by Dr. Ofer Daphna, CEO Nahum Ferera MD, and Dr. Arie Marcovich, MD., and develops advanced technology to treat acute problems in the ophthalmic world. The latest round brings the total amount of capital raised by the company to $36 million.
The new capital will be used to expand the clinical trials of EyeYon Medical's flagship product, the EndoArt®, the world's first synthetic implant which enables doctors to treat chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue. With nearly 13 million patients on the waiting list for corneal transplant, the EndoArt® was created in an effort to ease global shortages of corneal donations. Clinical trials, which are already underway in selected medical centers across Europe (IVRC in Heidelberg, Instituto de Microcirugia Ocular (IMO) in Barcelona, and AMC in Amsterdam) and in Israel (Soroka Medical Center, Rambam Health Care Campus, Tel Aviv Sourasky Medical Center and Barzilai Medical Center) have demonstrated the safety and efficacy of EyeYon Medical's groundbreaking technology.
Following the new investments, EyeYon Medical will expand its clinical trials with the aim to receive regulatory approval in the USA, China and Europe and leverage the company's extensive professional network and the high demand for the product.
"The overwhelming interest in joining our latest funding round reflects the confidence investors have in our unique and disruptive technology and its tremendous ability to address the clinical challenges and the huge market opportunity in the growing corneal implants market," said Nahum Ferera, Co-Founder and CEO of EyeYon Medical. "Together with our team of clinical and medical device experts, we have developed a novel solution which has already shown groundbreaking results and safety in human trials. The latest investments position EyeYon Medical as a global pioneer in the ophthalmology space and in corneal care."
"These resources will enable us to accelerate the clinical and regulatory phases in our key markets," said Dr. Ofer Daphna, Co-founder and the inventor of the EndoArt®. "EndoArt® will simplify corneal surgical procedures and can potentially empower any anterior segment surgeon to perform the surgery with a vision to eliminate the worldwide long waiting list for available human donor corneas."
"CR-CP is pleased to support EyeYon Medical on this innovative and meaningful advancement. We are confident that this will benefit underprivileged patients via affordable yet efficient treatment," said Da Liu, Managing Director of CR-CP Life Science Fund.
Richel Liu, CEO of Rimonci, said: "As the earlier stage investor, we continuously feel confident about the company's promising solution. We also believe that leveraging NMPA Innovation channel approval will facilitate the EndoArt® clinical penetration in China and make a contribution to eliminate China cornea blindness."
About EyeYon Medical
EyeYon Medical is a start-up company developing a variety of ophthalmic products for vision-threatening conditions. EyeYon Medical's flagship product is an Artificial Endothelial Layer - EndoArt®, a synthetic implant, attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction. A nonfunctioning endothelium results in corneal homeostasis loss due to excess fluid flowing into the cornea, resulting in severe vision loss. The minimally invasive EndoArt® is designed to replace dysfunctional endothelium to cure corneal Edema, offering a safer and simpler solution that will be available to anyone, anywhere. EyeYon Medical also developed the Hyper CL™, an FDA approved unique contact lens that acts as a premium therapeutic contact lens for a variety of corneal conditions which require eye drop treatment. For more information please visit https://eye-yon.com/.
Media contact
Yafit Lazar
Spokesperson
[email protected]
SOURCE EyeYon Medical
Share this article